Pyridostigmine reduces mortality of patients with severe SARS-CoV-2 infection: A phase 2/3 randomized controlled trial

Pyridostigmine reduces mortality of patients with severe SARS-CoV-2 infection: A phase 2/3 randomized controlled trial

Abstract: Background: Respiratory failure in severe coronavirus disease 2019 (COVID-19) is associated with a severe inflammatory response. Acetylcholine (ACh) reduces systemic inflammation in experimental bacterial and viral infections. Pyridostigmine increases the half-life of endogenous ACh, poten...

Full description

Bibliographic Details
Main Authors: Sergio Fragoso-Saavedra, Isaac Núñez, Belem M. Audelo-Cruz, Sarahi Arias-Martínez, Daniel Manzur-Sandoval, Alejandro Quintero-Villegas, H. Benjamín García-González, Sergio L. Carbajal-Morelos, Sergio PoncedeLeón-Rosales, José Gotés-Palazuelos, José A. Maza-Larrea, J. Javier Rosales-de la Rosa, Dafne Diaz-Rivera, Edgar Luna-García, Elvira Piten-Isidro, Perla M. Del Río-Estrada, Mario Fragoso-Saavedra, Yanink Caro-Vega, Isabella Batina, León Islas-Weinstein, David A. Iruegas-Nunez, Juan J. Calva, Pablo F. Belaunzarán-Zamudio, Juan Sierra-Madero, José C. Crispín, Sergio Iván Valdés-Ferrer
Format: Article
Language:English
Published: BMC 2022-11-01
Series:Molecular Medicine
Subjects:
COVID-19
SARS-CoV-2
Mortality
Invasive mechanical ventilation
Immunomodulation
Pyridostigmine
Online Access:https://doi.org/10.1186/s10020-022-00553-x

Internet

https://doi.org/10.1186/s10020-022-00553-x

Similar Items